Susan Schneider Thomas is a shareholder in the Consumer Fraud
and Whistleblower/Qui Tam practice groups at
Berger & Montague. She concentrates her practice on
qui tam litigation.
Ms. Thomas has substantial complex litigation experience.
Before joining Berger & Montague, she practiced law at two
Philadelphia area firms, Schnader, Harrison, Segal & Lewis and
Greenfield & Chimicles, where she was actively involved in the
litigation of complex securities fraud and derivative actions.
Upon joining Berger & Montague, Ms. Thomas concentrated her
practice on complex securities and derivative actions. In
1986, she joined in establishing Zlotnick & Thomas where
she was a partner with primary responsibility for the litigation of
several major class actions including Geist v. New Jersey
Turnpike Authority, C.A. No. 92-2377 (D.N.J.), a bond
redemption case that settled for $2.25 million and Burstein
v. Applied Extrusion Technologies, C.A. No. 92-12166-PBS (D.
Mass.), which settled for $3.4 million.
Upon returning to Berger & Montague, Ms. Thomas has had
major responsibilities in many securities and consumer fraud class
actions, including In re CryoLife Securities
Litigation, C.A. No. 1:02-CV-1868 BBM (N.D.Ga.), which
settled in 2005 for $23.25 million and In re First Alliance
Mortgage Co., Civ. No. SACV 00-964 (C.D.Cal.), a deceptive
mortgage lending action which settled for over $80 million in
cooperation with the FTC. More recently, Ms. Thomas has
concentrated her practice in the area of healthcare qui
tam litigation. As co-counsel for a team of whistleblowers,
she worked extensively with the U.S. Department of Justice and
various State Attorney General offices in the prosecution of False
Claims Act cases against pharmaceutical manufacturers that
recovered more than $2 billion for Medicare and Medicaid programs
and over $350 million for the whistleblowers. She has investigated
or is litigating False Claims Act cases involving defense
contractors, off-label marketing by drug and medical device
companies, federal grant fraud, upcoding and other billing issues
by healthcare providers, drug pricing issues and fraud in
connection with for-profit colleges and student loan programs.